HIA
CSTL icon

Harbor Investment Advisory’s Castle Biosciences CSTL Stock Holding History

Harbor Investment Advisory’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-542
Closed -$24K – 1341
2022
Q1 		$24K Hold
542
– – ﹤0.01% 904
2021
Q4 		$23K Hold
542
– – ﹤0.01% 905
2021
Q3 		$36K Buy
+542
New +$38.1K ﹤0.01% 823

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Harbor Investment Advisory's CSTL Position: Q2 2022 in Review

Harbor Investment Advisory sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 542 shares — an estimated $24K sold.

Harbor Investment Advisory first reported a position in CSTL in Q3 2021 and held it in 3 quarters. The position peaked at $36K in Q3 2021. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • Harbor Investment Advisory reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • Harbor Investment Advisory sold 542 Castle Biosciences shares in Q2 2022, an estimated $24K.
  • Harbor Investment Advisory first reported a position in Castle Biosciences in Q3 2021 and held it in 3 quarters.
  • Harbor Investment Advisory's Castle Biosciences position peaked at $36K in Q3 2021.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Harbor Investment Advisory's 13F filing for Q2 2022, filed 18 Jul 2022.